AstraZeneca in talks to buy cancer drugmaker Acerta for $5 billion: WSJ

(Reuters) – British drugmaker AstraZeneca Plc is in advanced talks to buy privately held cancer drug developer Acerta Pharma BV for more than $5 billion, the Wall Street Journal reported, citing people familiar with the matter.


Source: ReuterBusiness

Related posts